[Advances of neoadjuvant and conversion therapy with PD-1 inhibitors in gastric cancer]

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Gastric cancer (GC) is a prevalent digestive system malignancy in China.
• Immunotherapy, particularly programmed death receptor-1 (PD-1) inhibitors, is advancing treatment options for advanced GC.
• Recent clinical studies highlight immunotherapy's efficacy in neoadjuvant and conversion therapy for advanced GC.

Purpose of the Study:

• To review the current research progress on PD-1 inhibitors in gastric cancer treatment.
• To focus on the application of PD-1 inhibitors in neoadjuvant and conversion therapy for advanced GC.

Main Methods:

• Literature review of recent domestic and international clinical studies.
• Analysis of research progress on PD-1 inhibitors in GC therapy.

Main Results:

• Immunotherapy, including PD-1 inhibitors, demonstrates improved efficacy in neoadjuvant and conversion therapy settings for advanced GC.
• Growing evidence supports the role of PD-1 inhibitors in enhancing treatment outcomes for advanced gastric cancer patients.

Conclusions:

• PD-1 inhibitor-based combinatory therapy represents a significant advancement in treating advanced gastric cancer.
• Further research into PD-1 inhibitors for neoadjuvant and conversion therapy is warranted to optimize treatment strategies for gastric cancer.